Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.48 |
| ▸ | CTSA | P10619 | 3/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926870 | 0.90 | ACLY (0.52) | ACLYKCNA5CTSAPTGES2CYP26A1 | |
| SCHEMBL5926355 | 0.89 | CTSA (0.46) | ACLYKCNA5CTSACYP26A1CCKAR | |
| SCHEMBL5926378 | 0.88 | KCNA5 (0.47) | KCNA5CTSA | |
| SCHEMBL5926476 | 0.87 | ACLY (0.52) | ACLYKCNA5CTSACYP26A1CCKAR | |
| SCHEMBL5926687 | 0.85 | KCNA5 (0.49) | ACLYKCNA5CYP26A1 | |
| SCHEMBL5927106 | 0.85 | CCKAR (0.53) | ACLYKCNA5CCKARCCKBR | |
| SCHEMBL5926310 | 0.84 | METAP2 (0.49) | KCNA5CTSA | |
| SCHEMBL6098358 | 0.84 | METAP2 (0.49) | KCNA5CTSA | |
| SCHEMBL5926580 | 0.80 | KCNA5 (0.47) | ACLYKCNA5CTSACYP26A1 | |
| SCHEMBL5927453 | 0.80 | KCNA5 (0.51) | KCNA5MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | ACLY 2345/4885KCNA5 442/4885CTSA 638/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ACLY 3952/4885KCNA5 1021/4885CTSA 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.